Hareth Nahi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9436894/publications.pdf

Version: 2024-02-01

201 papers	9,302 citations	71102 41 h-index	43889 91 g-index
204 all docs	204 docs citations	204 times ranked	8524 citing authors

#	Article	IF	Citations
1	Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica, 2023, 108, 890-897.	3.5	65
2	Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group. European Journal of Haematology, 2022, 108, 34-44.	2.2	10
3	Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia, 2022, 36, 1066-1077.	7.2	39
4	Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. Cell Reports Medicine, 2022, 3, 100508.	6.5	20
5	Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment. Transplantation and Cellular Therapy, 2022, 28, 258.e1-258.e8.	1.2	4
6	Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica, 2022, 107, 2408-2417.	3.5	19
7	Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study. Cancer Reports, 2022, 5, e1614.	1.4	1
8	Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2022, 387, 495-505.	27.0	291
9	Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). Haematologica, 2021, 106, 1725-1732.	3.5	25
10	Exposureâ€Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. Journal of Clinical Pharmacology, 2021, 61, 614-627.	2.0	12
11	Dynamic followâ€up of smoldering multiple myeloma identifies a subset of patients at high risk of progression. American Journal of Hematology, 2021, 96, E63-E65.	4.1	5
12	Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. Journal of Clinical Oncology, 2021, 39, 227-237.	1.6	22
13	Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder. Blood, 2021, 137, 1260-1263.	1.4	5
14	Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma. American Journal of Hematology, 2021, 96, 23-30.	4.1	5
15	Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results. Journal of Cancer Research and Clinical Oncology, 2021, 147, 619-631.	2.5	17
16	Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden. Acta Haematologica, 2021, 144, 519-527.	1.4	0
17	Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study. Annals of Hematology, 2021, 100, 1065-1077.	1.8	6
18	Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups. European Journal of Haematology, 2021, 106, 546-554.	2.2	1

#	Article	IF	Citations
19	Pyoderma gangrenosum with plasma cell dyscrasia should be subject for antiâ€myeloma treatment. International Journal of Dermatology, 2021, 60, e271-e273.	1.0	1
20	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	10.7	136
21	Involved free light chain: an early independent predictor of response and progression in multiple myeloma. Leukemia and Lymphoma, 2021, 62, 2227-2234.	1.3	4
22	Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) Ã— CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).. Journal of Clinical Oncology, 2021, 39, 8007-8007.	1.6	14
23	Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14). American Journal of Hematology, 2021, 96, 925-933.	4.1	7
24	Predicting Drug Resistance by Single-Cell RNASeq in Patients with Multiple Myeloma. Clinical Chemistry, 2021, 67, 1309-1311.	3.2	2
25	Teclistamab, a B-cell maturation antigenâ€Ã—â€CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet, The, 2021, 398, 665-674.	13.7	138
26	Antibody response to <scp>COVID</scp>â€19 <scp>mRNA</scp> vaccine (<scp>Comirnaty</scp>) in myeloma patients treated with highâ€dose melphalan and/or immunotherapy. American Journal of Hematology, 2021, 96, E443-E446.	4.1	7
27	MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S424-S425.	0.4	1
28	Poster: MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S252.	0.4	0
29	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 1582-1596.	10.7	141
30	OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S1.	0.4	0
31	CD38 Down-Regulation on Ex Vivo Activated and Expanded NK Cells for Cell Therapy Persists after Infusion. Blood, 2021, 138, 4796-4796.	1.4	0
32	Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial. Blood, 2021, 138, 1655-1655.	1.4	0
33	Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. Blood, 2021, 138, 896-896.	1.4	29
34	Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study. Blood, 2021, 138, 1667-1667.	1.4	1
35	Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA. Blood, 2021, 138, 4095-4095.	1.4	0
36	Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose. Blood, 2021, 138, 1646-1646.	1.4	1

#	Article	IF	Citations
37	P-184: Regional differences in treatment and outcome for myeloma patients in Sweden: a population based Swedish Myeloma Register study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S138.	0.4	0
38	Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. Bone Marrow Transplantation, 2020, 55, 356-366.	2.4	12
39	Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis. Acta Haematologica, 2020, 143, 500-503.	1.4	7
40	Outcome and characteristics of nonâ€•measurable myeloma: A cohort study with populationâ€based data from the Swedish Myeloma Registry. European Journal of Haematology, 2020, 104, 376-382.	2.2	8
41	Outcome of COVIDâ€19 in multiple myeloma patients in relation to treatment. European Journal of Haematology, 2020, 105, 751-754.	2.2	17
42	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematology,the, 2020, 7, e370-e380.	4.6	170
43	Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Realâ€life outcomes of daratumumab treatment. European Journal of Haematology, 2020, 105, 196-202.	2.2	10
44	Treosulfan conditioning for allogeneic transplantation in multiple myeloma â€“ improved overall survival in first line haematopoietic stem cell transplantation â€“ a large retrospective study by the Chronic Malignancies Working Party of the EBMT. British Journal of Haematology, 2020, 189, e213-e217.	2.5	10
45	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematology,the, 2020, 7, e447-e455.	4.6	74
46	Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients. Blood, 2020, 136, 20-20.	1.4	4
47	A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients. Blood, 2020, 136, 40-41.	1.4	4
48	Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 27-27.	1.4	51
49	Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).. Journal of Clinical Oncology, 2020, 38, 100-100.	1.6	37
50	Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study.. Journal of Clinical Oncology, 2020, 38, 8537-8537.	1.6	1
51	Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 1-2.	1.4	2
52	Multiple myeloma in patients up to 30Âyears of age: a multicenter retrospective study of 52 cases. Leukemia and Lymphoma, 2019, 60, 471-476.	1.3	13
53	A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor. Biology of Blood and Marrow Transplantation, 2019, 25, 34-40.	2.0	9
54	Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. Leukemia and Lymphoma, 2019, 60, 163-171.	1.3	11

#	Article	IF	Citations
55	Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood, 2019, 134, 668-677.	1.4	87
56	Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?. European Journal of Haematology, 2019, 103, 588-596.	2.2	24
57	Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma. European Journal of Haematology, 2019, 103, 247-254.	2.2	11
58	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. New England Journal of Medicine, 2019, 380, 2104-2115.	27.0	684
59	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 781-794.	10.7	254
60	Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PLoS ONE, 2019, 14, e0211927.	2.5	85
61	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. Haematologica, 2019, 104, 2358-2360.	3.5	18
62	Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e225-e226.	0.4	0
63	Greater Treatment Satisfaction in Patients Receiving Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) for Relapsed or Refractory Multiple Myeloma (RRMM): COLUMBA. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e247-e248.	0.4	2
64	Novel RNA construct increases cytotoxic proteins in lymphocytes and leads to prolonged survival in an experimental syngeneic immunocompetent Multiple Myeloma model. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e170.	0.4	0
65	Reinstating anti-tumor activity of Natural Killer cells. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e158.	0.4	0
66	Over 10 years relative median survival in MM patients â‰¥ 65 years with VGPR or better on 1st line treatment. Population-based data on patients diagnosed 2008-2018 from the Swedish Myeloma Registry. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e209.	0.4	0
67	PF592 IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA. HemaSphere, 2019, 3, 248-249.	2.7	0
68	S1602 CARFILZOMIB AND DEXAMETHASONE MAINTENANCE PROLONG TIME TO PROGRESSION. HemaSphere, 2019, 3, 737-738.	2.7	1
69	A phase 2 study of carfilzomib plus elotuzumab plus dexamethasone for myeloma patients relapsed after 1-3 prior treatment lines. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e279-e280.	0.4	0
70	Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma â€“ Improved Overall Survival in first line Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e206.	0.4	0
71	All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. European Journal of Cancer, 2019, 106, 89-98.	2.8	25
72	Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells. Cancers, 2019, 11, 69.	3.7	21

#	Article	IF	Citations
73	A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group. Blood, 2019, 134, 601-601.	1.4	5
74	Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba. Blood, 2019, 134, 1906-1906.	1.4	5
75	Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update. Blood, 2019, 134, 1865-1865.	1.4	14
76	Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. Blood, 2019, 134, 1875-1875.	1.4	26
77	Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017. Blood, 2019, 134, 4575-4575.	1.4	3
78	Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.. Journal of Clinical Oncology, 2019, 37, 8005-8005.	1.6	15
79	Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.. Journal of Clinical Oncology, 2019, 37, 8035-8035.	1.6	4
80	Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis. Blood, 2019, 134, 3151-3151.	1.4	0
81	Lenalidomide versus lenalidomideÂ+Âdexamethasone prolonged treatment after secondâ€line lenalidomideÂ+Âdexamethasone induction in multiple myeloma. Cancer Medicine, 2018, 7, 2256-2268.	2.8	1
82	The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression. Nature Communications, 2018, 9, 1649.	12.8	22
83	Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma. Blood, 2018, 131, 2138-2150.	1.4	77
84	Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial. Cancer Chemotherapy and Pharmacology, 2018, 81, 183-193.	2.3	16
85	Outcome and survival of myeloma patients diagnosed 2008â€“2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica, 2018, 103, 506-513.	3.5	103
86	Case Report: Treatment of lightâ€chain amyloidosis with daratumumab monotherapy in two patients. European Journal of Haematology, 2018, 100, 386-388.	2.2	17
87	Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nature Communications, 2018, 9, 3707.	12.8	86
88	Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). Blood, 2018, 132, LBA-2-LBA-2.	1.4	30
89	Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO). Blood, 2018, 132, 2006-2006.	1.4	8
90	A Phase 2 Study of Carfilzomib Plus Elotuzumab Plus Dexamethasone for Myeloma Patients Relapsed after 1-3 Prior Treatment Lines. Blood, 2018, 132, 1975-1975.	1.4	1

#	Article	IF	Citations
91	Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).. Journal of Clinical Oncology, 2018, 36, 8013-8013.	1.6	6
92	Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma (RRMM): COLUMBA.. Journal of Clinical Oncology, 2018, 36, TPS8058-TPS8058.	1.6	4
93	Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma Improved Overall Survival in Upfront Hematopoietic Stem Cell Transplantation â€" a Large Retrospective Study By the Chronic Malignancies Working Party of the EBMT. Blood, 2018, 132, 3464-3464.	1.4	0
94	Impact of Upfront Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma with Del(17) and t(4;14): A Report from the EBMT Chronic Malignancies Working Party. Blood, 2018, 132, 2143-2143.	1.4	2
95	Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO). Blood, 2018, 132, 1995-1995.	1.4	1
96	Long-Lasting Remissions for Myeloma Patients on Daratumumab Therapy from the GEN501 and GEN503 Trials. Blood, 2018, 132, 3308-3308.	1.4	0
97	Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia, 2017, 31, 2443-2448.	7.2	259
98	Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Populationâ€based data from the Swedish Myeloma Register. European Journal of Haematology, 2017, 99, 216-222.	2.2	48
99	Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Leukemia, 2017, 31, 2435-2442.	7.2	18
100	Effects of singleâ€agent bortezomib as postâ€transplant consolidation therapy on multiple myelomaâ€related bone disease: a randomized phase <scp>II</scp> study. British Journal of Haematology, 2017, 178, 61-71.	2.5	12
101	IgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology, 2017, 92, 746-751.	4.1	45
102	An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM). Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S333-S334.	0.4	2
103	Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma. Value in Health, 2017, 20, A408.	0.3	5
104	Direct evidence for a polygenic etiology in familial multiple myeloma. Blood Advances, 2017, 1, 619-623.	5.2	15
105	Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study. Blood, 2017, 130, 838-838.	1.4	19
106	Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).. Journal of Clinical Oncology, 2017, 35, 8025-8025.	1.6	4
107	EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. Oncotarget, 2017, 8, 10213-10224.	1.8	47
108	The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains. Oncotarget, 2017, 8, 103731-103743.	1.8	19

#	Article	IF	Citations
109	Abstract 5030: The impact ofABCB1single nucleotide polymorphisms on the outcome in lenalidomide treated multiple myeloma patients. , 2017, , .		0
110	Central nervous system involvement by multiple myeloma: A multiâ€institutional retrospective study of 172 patients in daily clinical practice. American Journal of Hematology, 2016, 91, 575-580.	4.1	83
111	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Drugs, 2016, 76, 853-867.	10.9	34
112	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood, 2016, 128, 37-44.	1.4	347
113	Characteristics and outcomes of patients with multiple myeloma aged 21â€“40Âyears versus 41â€“60Âyears: a multiâ€institutional caseâ€control study. British Journal of Haematology, 2016, 175, 884-891.	2.5	21
114	Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994â€“2009. Bone Marrow Transplantation, 2016, 51, 1569-1572.	2.4	16
115	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016, 375, 1319-1331.	27.0	1,210
116	Reâ€challenging with antiâ€CD38 monotherapy in tripleâ€refractory multiple myeloma patients is a feasible and safe approach. British Journal of Haematology, 2016, 174, 473-477.	2.5	19
117	Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nature Communications, 2016, 7, 12050.	12.8	146
118	Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. Acta OncolÃ³gica, 2016, 55, 554-560.	1.8	14
119	Health resource utilization associated with skeletal-related events: results from a retrospective European study. European Journal of Health Economics, 2016, 17, 711-721.	2.8	16
120	Proteasome inhibitors and <scp>IM</scp>iDs can overcome some highâ€risk cytogenetics in multiple myeloma but not gain 1q21. European Journal of Haematology, 2016, 96, 46-54.	2.2	35
121	Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO). Blood, 2016, 128, 1149-1149.	1.4	20
122	Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone. Blood, 2016, 128, 246-246.	1.4	28
123	An open-label, dose-escalation phase 1b study of subcutaneous daratumumab with recombinant human hyaluronidase in patients with relapsed or refractory multiple myeloma (PAVO).. Journal of Clinical Oncology, 2016, 34, TPS8071-TPS8071.	1.6	2
124	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. Blood, 2016, 128, 3276-3276.	1.4	0
125	Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol. Blood, 2016, 128, 5692-5692.	1.4	0
126	Impact of Extramedullary Disease in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: A Study By the EBMT Chronic Malignancies Working Party. Blood, 2016, 128, 2266-2266.	1.4	1

#	Article	IF	Citations
127	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. Blood, 2016, 128, 4414-4414.	1.4	0
128	A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2015, 21, 2730-2736.	7.0	41
129	A genealogical and clinical study of the phenotypical variation within the Swedish transthyretin His88Arg (p. His108Arg) amyloidosis family. European Journal of Medical Genetics, 2015, 58, 211-215.	1.3	10
130	Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Bone Marrow Transplantation, 2015, 50, 808-812.	2.4	34
131	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, BloodÂand Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 2039-2051.	2.0	146
132	Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. Nature Communications, 2015, 6, 7213.	12.8	101
133	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. New England Journal of Medicine, 2015, 373, 1207-1219.	27.0	948
134	<scp>TP</scp>53 mutations and MDM2^{SNP309} identify subgroups of <scp>AML</scp> patients with impaired outcome. European Journal of Haematology, 2015, 94, 355-362.	2.2	13
135	Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070). Blood, 2015, 126, 26-26.	1.4	16
136	Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma. Blood, 2015, 126, 29-29.	1.4	7
137	The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex. Blood, 2015, 126, 3047-3047.	1.4	1
138	Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma. PLoS ONE, 2015, 10, e0138248.	2.5	7
139	Re-Challenging with Anti-CD38 Monotherapy in Triple-Refractory Multiple Myeloma Patients Is a Feasible and Safe Approach. Blood, 2015, 126, 5366-5366.	1.4	0
140	Impact of <scp>ABCB</scp>1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in <scp>FLT</scp>3 wildâ€type de novo <scp>AML</scp> patients with normal karyotype. British Journal of Haematology, 2014, 167, 671-680.	2.5	13
141	Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma â€“ a retrospective population based study of 1162 patients. European Journal of Haematology, 2014, 92, 19-25.	2.2	4
142	Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population. British Journal of Haematology, 2014, 164, 684-693.	2.5	38
143	Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement. European Journal of Haematology, 2014, 92, 454-455.	2.2	15
144	Comparative Real World Effectiveness of Novel Agents Versus Conventional Therapies in Multiple Myeloma Patients in Sweden. Value in Health, 2014, 17, A545-A546.	0.3	0

#	Article	IF	Citations
145	Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT). Value in Health, 2014, 17, A617-A618.	0.3	0
146	Bortezomib Re-treatment in Patients with Multiple Myeloma (MM). A Real World Medical Practice Experience from a Swedish National Registry. Value in Health, 2014, 17, A617.	0.3	0
147	European Perspective on Multiple Myeloma Treatment Strategies in 2014. Oncologist, 2014, 19, 829-844.	3.7	90
148	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncology, The, 2014, 15, 1195-1206.	10.7	695
149	Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial. Blood, 2014, 124, 3458-3458.	1.4	1
150	Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).. Journal of Clinical Oncology, 2014, 32, 8513-8513.	1.6	19
151	The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment. PLoS ONE, 2014, 9, e101819.	2.5	49
152	In search of the molecular consequences of 8p21 deletion in multiple myeloma: commentary on GmidÃ©ne et al. Medical Oncology, 2013, 30, 569.	2.5	1
153	A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens: Results from a Swedish Retrospective Analysis. Acta Haematologica, 2013, 130, 7-15.	1.4	5
154	Decreased survival in normal karyotype AML with singleâ€nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5â€²â€nucleotidase. American Journal of Hematology, 2013, 88, 1001-1006.	4.1	28
155	Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood, 2013, 121, 4647-4654.	1.4	128
156	Real World Data In Myeloma: Experiences From The Swedish Population-Based Registry On 2494 Myeloma Patients Diagnosed 2008-2011. Blood, 2013, 122, 1972-1972.	1.4	4
157	Abstract 1170: Correlation between cytidine deaminase single nucleotide polymorphisms andin vitrodrug sensitivity, DNA methylation and outcome in normal karyotype acute myelogenous leukemia.. , 2013, , .		0
158	Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. Pharmacogenomics Journal, 2012, 12, 111-118.	2.0	38
159	Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery. Medical Oncology, 2012, 29, 2191-2199.	2.5	20
160	Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution. Medical Oncology, 2012, 29, 2348-2358.	2.5	3
161	Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation. Medical Oncology, 2012, 29, 1231-1236.	2.5	32
162	Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. European Journal of Haematology, 2012, 88, 485-496.	2.2	42

#	Article	IF	Citations
163	Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population.. Blood, 2012, 120, 2970-2970.	1.4	1
164	Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study. Blood, 2012, 120, 73-73.	1.4	60
165	Is Renal Impairment Still a Poor Prognostic Marker in Myeloma Care?: A Population Based Study Including 1542 Patients. Blood, 2012, 120, 5033-5033.	1.4	0
166	Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. Blood, 2011, 118, 5573-5582.	1.4	67
167	Clinical impact of chromosomal aberrations in multiple myeloma. Journal of Internal Medicine, 2011, 269, 137-147.	6.0	35
168	APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. European Journal of Haematology, 2011, 86, 206-215.	2.2	61
169	Acquired hemophagocytic lymphohistiocytosis associated with multiple myeloma. Medical Oncology, 2011, 28, 539-543.	2.5	21
170	Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective. Oncologist, 2011, 16, 388-403.	3.7	26
171	A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma â€“ Preliminary Safety Data. Blood, 2011, 118, 1873-1873.	1.4	2
172	Follow-up of Real Life Treated Multiple Myeloma Patients: Response, Disease Progression and Overall Survival,. Blood, 2011, 118, 3937-3937.	1.4	0
173	Constitutional inv(3) in myelodysplastic syndromes. Leukemia Research, 2010, 34, 1627-1629.	0.8	3
174	Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia, 2010, 24, 932-941.	7.2	113
175	Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy, 2010, 12, 1044-1055.	0.7	112
176	Abstract 2757: NT5C2 single nucleotide polymorphisms affects survival and response inde novoAML patients with normal karyotype. , 2010, , .		0
177	Global and HOX Gene DNA Methylation In Normal Karyotype Acute Myeloid Leukemia: Clinical Implications and Molecular Correlations. Blood, 2010, 116, 231-231.	1.4	0
178	Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation. Oncology Reports, 2009, 22, 137-42.	2.6	7
179	The prognostic significance of 8p21 deletion in multiple myeloma. British Journal of Haematology, 2009, 144, 266-268.	2.5	16
180	Low p14ARF expression inde novoacute myeloid leukemia with normal karyotype is associated with poor survival. Leukemia and Lymphoma, 2009, 50, 1512-1518.	1.3	4

#	Article	IF	Citations
181	Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial.. Blood, 2009, 114, 530-530.	1.4	19
182	Implications On Drug Resistance and Survival of ABCB1 Single Nucleotide Polymorphisms in Normal Karyotype De Novo AML.. Blood, 2009, 114, 2648-2648.	1.4	0
183	In Vitro and Ex Vivo Studies On Cell Lines and Primary Human Leukemia Cells of the Effects of APR-246 Alone and in Combination with Conventional Chemotherapeutic Drugs.. Blood, 2009, 114, 2751-2751.	1.4	0
184	The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2008, 62, 439-448.	2.3	32
185	Mutated and nonâ€mutated TP53 as targets in the treatment of leukaemia. British Journal of Haematology, 2008, 141, 445-453.	2.5	51
186	Transmission of chronic lymphocytic leukaemia from a blood stem cell sibling donor to the recipient. British Journal of Haematology, 2008, 143, 751-753.	2.5	5
187	Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. Leukemia and Lymphoma, 2008, 49, 508-516.	1.3	29
188	Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood, 2008, 111, 3155-3162.	1.4	171
189	An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients. Haematologica, 2008, 93, 1734-1738.	3.5	17
190	Low Expression of p14ARF in De Novo AML with Normal Karyotype Is Associated with Short Survival but Increased in Vitro Sensitivity to p53 Modulating Drugs. Blood, 2008, 112, 2937-2937.	1.4	0
191	Impact of Chromosome 13 Deletion and Plasma Cell Load on Long-Term Survival of Patients with Multiple Myeloma Undergoing Autologous Transplantation. Blood, 2008, 112, 5148-5148.	1.4	0
192	Do Deletions in 9p Reflect Prognosis in Adult Precursor B-Cell ALL? a Multi-Centre Study of 381 Patients. Blood, 2008, 112, 4865-4865.	1.4	0
193	The Prognostic Significance of 8p21 Deletion in Multiple Myeloma. Blood, 2008, 112, 5153-5153.	1.4	0
194	Different Incidence and Implications of DNA Hypermethylation in De Novo AML Compared to High-Risk MDS and AML Following MDS.. Blood, 2008, 112, 3337-3337.	1.4	0
195	Topoisomerase IIÎ± mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia. International Journal of Oncology, 2007, , .	3.3	1
196	Expression of p14ARF in De Novo AML with Normal Karyotype. Implication on Drug Resistance and Survival.. Blood, 2007, 110, 4261-4261.	1.4	6
197	PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. British Journal of Haematology, 2006, 132, 230-236.	2.5	57
198	Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. British Journal of Haematology, 2006, 135, 367-373.	2.5	56

#	Article	IF	Citations
199	Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. British Journal of Haematology, 2005, 130, 96-98.	2.5	101
200	RITA Activates p53 Function in Chronic Lymphocytic Leukaemia Cells and Induces Apoptosis.. Blood, 2005, 106, 5536-5536.	1.4	0
201	Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. British Journal of Haematology, 2004, 127, 285-291.	2.5	53